R&D Expensing is Back: A Lifeline for Small Tech & Manufacturers
For small tech startups, software developers, biotech innovators, and manufacturers, the Tax Cuts and Jobs Act (TCJA) amortization requirement under Section 174 since 2022 has been a severe cash flow drain. The mandate to capitalize and amortize domestic R&D costs over five years (15 for foreign) forced many to delay innovation, cut staff, or face higher effective taxes—despite investing heavily in U.S.-based research.
The One Big Beautiful Bill Act (OBBBA), signed July 4, 2025, delivers high-stakes relief: permanent restoration of immediate expensing for domestic R&D under new Section 174A, effective for tax years beginning after December 31, 2024. This reversal is a critical lifeline, unlocking immediate deductions, improving cash flow, and boosting competitiveness in 2026 and beyond.
The High-Stakes Shift: From Amortization to Immediate Expensing
Pre-2022, businesses deducted domestic R&D expenses (wages, supplies, contract research) in the year incurred. The TCJA changed that, requiring capitalization and amortization—hitting cash-strapped small businesses hardest. Now, under OBBBA’s Section 174A, qualified domestic R&E costs are fully deductible in the year paid or incurred, simplifying compliance and providing immediate tax relief.
Foreign R&D remains amortized over 15 years. Software development qualifies as domestic R&E if performed in the U.S.—a major win for tech firms.
Retroactive Relief: The Critical Window for Small Businesses
Eligible small businesses (average gross receipts ≤ $31 million over prior 3 years, per Section 448(c)) can elect retroactive application to tax years 2022-2024. This means amending returns to fully deduct previously amortized domestic R&D costs—potentially generating substantial refunds.
Deadline: Elect and file amendments by July 4, 2026 (or earlier for some refund claims). Act now—delays could forfeit cash flow recovery.
Catch-Up Options for All Businesses (Including Larger Ones)
For unamortized domestic R&D from 2022-2024:
| Business Size | Retroactive Amendment | Catch-Up Deduction Options |
|---|---|---|
| Small (≤ $31M receipts) | Yes (2022-2024) | Full in 2025 or split 2025-2026; plus retroactive |
| Larger (> $31M) | No | Full remaining in 2025 or 50/50 over 2025-2026 |
Model scenarios carefully—consider bracket changes, NOLs, and Section 280C credit reductions.
Interaction with R&D Tax Credit (Section 41): More Value Than Ever
Immediate expensing increases qualified research expenses (QREs), amplifying the credit. However, coordinate via Section 280C: reduce deduction by credit amount or elect reduced credit. Small businesses amending returns must adjust accordingly.
R&D Retroactive Refund Checklist
Our step-by-step checklist helps determine eligibility, gather documentation, model refunds vs. catch-up, and decide on amendments for 2022-2024. Secure your cash flow recovery today.
Frequently Asked Questions
What changed with Section 174 R&D expensing in 2026?
The OBBBA permanently restores immediate expensing for domestic R&D costs under new Section 174A for tax years beginning after Dec. 31, 2024. Domestic expenses are fully deductible in the year incurred, ending the TCJA’s 5-year amortization requirement.
Who qualifies for retroactive relief on 2022-2024 R&D amortization?
Small businesses with average annual gross receipts of $31 million or less (Section 448(c) test) can elect retroactive expensing by amending 2022-2024 returns. Deadline: July 4, 2026.
What options do larger businesses have for unamortized 2022-2024 R&D costs?
Accelerate remaining unamortized domestic R&D costs: full deduction in 2025 or split 50/50 over 2025-2026. No retroactive amendments allowed.
How does restored expensing affect the R&D tax credit (Section 41)?
Immediate expensing increases qualified research expenses, making the credit more valuable. Coordinate with Section 280C reductions; small businesses may need to adjust credits on amended returns.
Does foreign R&D qualify for immediate expensing?
No—foreign R&D remains subject to 15-year amortization under Section 174.
This restoration is a high-stakes turning point—don’t miss the window for relief. Contact Nexus Tax Books for expert analysis of your R&D position and optimal strategy in 2026.